Business Development Inquiry

Alzheimacy was founded based on a firm scientific belief that the rapid development of biotechnology will enable people to better understand Alzheimer’s disease (AD) and obtain solutions for the diagnosis, prevention, and treatment of this disease. We believe that no other disease needs or promises a medical breakthrough like AD. Alzheimacy hopes to work with global partners to fight AD and hopes to build a sustainable and profitable biotechnology company.

For Academic Partners

No single company, institution, university or government agency can solve global health problems on its own. In the face of the challenge, our strategy is to work with anyone with cutting-edge knowledge and technology to further improve the efficiency of the research and development of effective therapeutics for AD.

We are open to opportunities such as global licensing and co-development. We choose to cooperate with the world’s leading biopharmaceutical companies, academic centers, universities, and other relevant organizations in various forms. Alzheimacy promises to share appropriate future revenue with our partners.

Alzheimacy sincerely welcomes scientists interested in the basic research on the pathogenesis of AD and development of therapeutics for this disease to perform your research projects by leveraging our platforms. Alzheimacy will claim commercial rights throughout the process through contracts, encourage joint publication of scientific discoveries, support related patent applications, and appropriately share the economic benefits of the research. For more information on partnership opportunities, please email info@creative-biomart.com

Why Alzheimacy?

• Long-term experience. Alzheimacy specializes in the development of innovative treatments for AD. Our professional and experienced technical team make us an expert partner for your AD therapeutics development projects.
• Integrated drug development capabilities. At Alzheimacy, we connect researchers with drug discovery experts, and drug discovery occurs in networks of biology, chemistry, structural biology, and in silico simulations, where reassessment and readjustment happen seamlessly in real time. Our comprehensive technology platform covers a wide range of technologies related to molecular biology, biochemistry, cell biology, structural biology, immunology, as well as animal model research, and can be applied to the development of various forms of drugs, including biological drugs, chemical drugs, and biologics.
• Superior design principles. We understand the regulatory challenges faced by drug developers. We comply with all GLP, GMP and GCP guidelines, and maintain a Quality Management System (QMS). Our superior design principles will consistently meet the requirements of the IND application at every stage of development.
• Flexible cooperation mode. We work extensively with leading scientist and leaders from academia and biopharmaceutical industry. Our partnership model allows for transparent sharing of information, coordinated decision-making and a high degree of flexibility.

For Investors

Alzheimacy is a biotechnology company dedicated to the introduction, development, and commercialization of innovative therapeutics for AD. Our company is currently in a period of rapid development and rising. We sincerely invite friends from the financial industry who are willing to develop with us to pay attention to and support the development of Alzheimacy, share with each other, face challenges together, and create a better future!

The value factors of Alzheimacy are as follows:

• Market. Good market positioning, focusing on the global market of AD, which is a huge and unmet market opportunity.
• Business model. The introduction of projects and internal research and development work along both lines. Leveraging important North American/Chinese synergies and effective competitive advantages in drug development and commercialization.
• Management. Experienced and motivated leadership to achieve superior management.
• Capital. Relying on successful venture capital funds and investors and adopting cost-effective financial management methods.
• Value drivers. Clear and meaningful short-term value drivers support long-term development.

For inquiries, please contact us at info@creative-biomart.com